Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




One-Third of Breast Cancer Cases Treated Unnecessarily

By HospiMedica International staff writers
Posted on 26 Jan 2017
A new study suggests that one in three women with breast cancer detected by a mammogram may be treated unnecessarily.

Researchers at the Nordic Cochrane Centre, the University of Oslo, and the Norwegian Institute of Public Health conducted a cohort study to assess the association between biennial mammography screening and the size of detected tumors in women aged 35 to 84 years, measuring trends in the incidence of advanced (>20 mm) and non-advanced (≤20 mm) breast cancer tumors in both screened and non-screened women.

Two approaches were used to estimate the amount of over-diagnosis. More...
The first compared the incidence of advance and non-advanced tumors among women aged 50-84 years in screening and non-screening areas; the second compared the incidence for non-advanced tumors among women aged 35-49, 50-69, and 70-84 years in screening and non-screening areas. The researchers assumed that if screenings work as intended, the number of small, curable breast tumors should increase, reducing the number of large cancers by about the same amount.

The results revealed that screening was not associated with lower incidence of advanced tumors. The first approach found 271 invasive breast cancer tumors and 179 ductal carcinoma in situ (DCIS) lesions over-diagnosed in 2010, an over-diagnosis rate of 24.4% (including DCIS) and 14.7% (excluding DCIS). The second approach, which accounted for regional differences in women younger than the screening age, found 711 invasive tumors and 180 cases of DCIS over-diagnosed in 2010, an over-diagnosis rate of 48.3% (including DCIS) and 38.6% (excluding DCIS). The study was published on January 10, 2017, in Annals of Internal Medicine.

“Breast cancer screening was not associated with a reduction in the incidence of advanced cancer. It is likely that one in every three invasive tumors and cases of DCIS diagnosed in women offered screening represent over-diagnosis,” concluded study coauthor Karsten Jorgensen, PhD, of the Nordic Cochrane Center, and colleagues. “Although mammograms in Denmark detected a lot more breast cancers, these were mostly small, early-stage tumors. The number of advanced cancers did not fall.”

DCIS is the most common type of non-invasive breast cancer, in which the abnormal cells are contained inside the milk ducts. If DCIS is not treated, it may eventually develop into invasive breast cancer, which can spread outside the ducts into the breast tissue and then possibly to other parts of the body. Since DCIS cannot usually be felt as a breast lump or other breast change, most cases are diagnosed following routine screening with mammograms or ultrasound, appearing as micro-calcifications.


Gold Member
12-Channel ECG
CM1200B
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Ultrasound Needle Guidance System
SonoSite L25
Floor‑Mounted Digital X‑Ray System
MasteRad MX30+
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Business

view channel
Image: The collaboration will integrate Masimo’s innovations into Philips’ multi-parameter monitoring platforms (Photo courtesy of Royal Philips)

Philips and Masimo Partner to Advance Patient Monitoring Measurement Technologies

Royal Philips (Amsterdam, Netherlands) and Masimo (Irvine, California, USA) have renewed their multi-year strategic collaboration, combining Philips’ expertise in patient monitoring with Masimo’s noninvasive... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.